bioTheranostics has reported findings from three studies using the company’s breast cancer molecular test. Data from the studies were presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).
The company said that the data reinforce the value of the Theros BCI as a tool that can help oncologists and patients make information-based decisions about breast cancer therapy.
The Theros Breast Cancer Index (BCI) is a combination of HOXB13:IL17BR (H/I) and Molecular Grade Index (MGI), biomarkers that improve risk stratification and treatment outcome prediction in patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer.
Reportedly, the data demonstrated that the Theros BCI assay provides reliable, quantitative and predictive information about individual patient’s disease recurrence risk, as well as therapeutic response to a commonly used aromatase inhibitor.
Richard Ding, CEO of bioTheranostics, said: “We are very excited about the outcome of these studies. Consistent with our previous work, this clinical evidence reinforces the clinical utility of the BCI assay. bioTheranostics is looking forward to providing this innovative diagnostic tool to clinicians to help improve risk-based and individualized treatment for breast cancer patients.”